About this trial
Based on the inclusion and exclusion criteria, patients with head and face PHN who met the requirements were selected as trial subjects, and the efficacy was clarified in a randomized controlled design trial. The visual analog score VAS was used as the primary evaluation index, and the depression self-assessment scale score , Hamilton depression scale, Pittsburgh sleep quality index scale, and quality of life evaluation scale (SF-36) were used as the secondary evaluation indexes, and oral pregabalin was used as the control group, and the subjects in the pregabalin and the plexus superficial stabbing combined with electroacupuncture groups were observed respectively at the time of Before treatment, immediately after the first treatment, after 2 days of treatment, after 2 weeks of treatment, after 4 weeks of treatment, after 1 month of follow-up after the end of treatment and after 2 months of follow-up after the end of treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial design
Parallel
Treatments tested in this trial
electroacupuncture
Other interventionThe patient takes the supine position, the whole body relaxes, the facial skin is routinely sterilized. Local acupuncture points along the head and face herpes zoster lesion branches with 0.18 × 25 mm millimetre needle series of shallow stabbing method row stabbing method.Han's Acupoint Neurostimulator (model HANS-200) was selected, local acupoints were chosen as Xiaguan+Quanliao or Xiaguan+Jiache, and distal acupoints were chosen as Hegu+Waiguan connected with electroacupuncture, sparse and dense wave 2/100 Hz was selected, and the treatment time was 60 minutes, and the intensity of the current was all to the extent that the patient could tolerate it. The needles were left in place for 60 minutes each time, once every other day, and the treatment was performed 3 times a week for 4 weeks, for a total of 12 treatments.
Pregabalin
DrugSubjects in this group will be treated with oral pregabalin capsules only, 150 mg twice daily for 4 weeks.Pregabalin was administered with Lerica (specification: 75 mg\*8 capsules,manufactured by Pfizer Pharmaceuticals Ltd).
Treatment groups
Trial outcomes
Primary outcomes
Visual Analogue Scale/Score
This scale is performed by two trained raters to perform a Self-rating depression scale(SDS), usually in the form of conversation and observation. After the examination, the two raters will score independently.Baseline values were taken from the pre-treatment assessment, mean values from weeks 1 and 2 of the treatment period were taken at mid-treatment (2 weeks), and mean values from weeks 3 and 4 of the treatment period were taken at the end of treatment (4 weeks). Daily mean values were taken for one month at one month follow-up and for two months at two months follow-up.
Secondary outcomes
Self-rating depression scale
This scale is performed by two trained raters to perform a Self-rating depression scale(SDS), usually in the form of conversation and observation. After the examination, the two raters will score independently.
Hamilton depression scale
This scale is performed by two trained raters to perform a Hamilton depression scale (HAMD), usually in the form of conversation and observation. After the examination, the two raters will score independently.
Pittsburgh Sleep Quality Index Scale
This scale is performed by two trained raters to perform a Pittsburgh Sleep Quality Index Scale(PSQI), usually in the form of conversation and observation. After the examination, the two raters will score independently.
Quality of Life Rating Scale
This scale is performed by two trained raters to perform aQuality of Life Rating Scale(SF-36), usually in the form of conversation and observation. After the examination, the two raters will score independently.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.